Detailed Information on Publication Record
2022
A Systematic Review of Cost-effectiveness Analyses of Durvalumab Consolidation Therapy Versus no Consolidation Therapy After Chemoradiotherapy in Stage-III NSCLC
HUSSAIN, Mohammad Salman, Jitka KLUGAROVÁ and Miloslav KLUGARBasic information
Original name
A Systematic Review of Cost-effectiveness Analyses of Durvalumab Consolidation Therapy Versus no Consolidation Therapy After Chemoradiotherapy in Stage-III NSCLC
Authors
HUSSAIN, Mohammad Salman, Jitka KLUGAROVÁ and Miloslav KLUGAR
Edition
GIN 2022, Toronto, 2022
Other information
Language
English
Type of outcome
Konferenční abstrakt
Field of Study
30230 Other clinical medicine subjects
Country of publisher
Czech Republic
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Organization unit
Faculty of Medicine
Keywords in English
Durvalumab; Cost-effectivness analysis; NSCLC
Změněno: 10/10/2022 14:43, Mgr. Bc. Alena Langaufová, Ph.D.
Abstract
V originále
Background Recently, Durvalumab was approved as a potential immunotherapy for the management of unresectable stage III NSCLC. To date, economic studies from different parts of the world presented varying findings. Objective So, the objective of this study was to assess the cost-effectiveness of durvalumab consolidation therapy versus no consolidation therapy in patients with unresectable stage III NSCLC. Methods PubMed, Embase, and Cochrane Central databases were searched till March 2022 to identify all the studies assessing the economic evaluation of durvalumab in patients with unresectable stage III NSCLC. Eligible studies were screened by two reviewers independently and the quality of included studies was evaluated using the updated version of CHEERS 2022 checklists. Incremental cost-effectiveness ratio (ICER) data were converted to 2022 US dollars ($). Results A total of seven studies were found to be eligible for inclusion. The healthcare payers’ perspective was the most common study perspective among the included studies. Four included studies used the Markov model. The ICER of durvalumab consolidation therapy after unresectable stage III NSCLC in the US was found to be in the range of $59,850 to $145,543 per Quality-Adjusted Life Years (QALY). Likewise, the ICER of durvalumab in European countries was found to be in the range of $62,021 to $76,068 per QALY. Durvalumab was found to be cost-effective among all the included studies as the ICER was below the implemented country-specific willingness-to-pay thresholds. Conclusion Durvalumab consolidation therapy was found to be cost-effective versus no consolidation therapy after chemoradiotherapy in stage-III NSCLC patients.